EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs

Tetsu Hirakawa, Kakuhiro Yamaguchi, Kiyofumi Shimoji, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Taku Nakashima, Hiroshi Iwamoto, Hironobu Hamada, Noboru Hattori

International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1696-1705

DOI: 10.1007/s10147-026-03083-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 09.06.2026. Verfasst von Tetsu Hirakawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiro…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Vascular Endothelial Growth Factor A, Protein Kinase Inhibitors, Lung Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vascular endothelial growth factor (VEGF)-A, which is overexpressed in epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC), has been implicated in resistance to EGFR-tyrosine kinase inhibitors (TKIs). VEGF-A comprises several isoforms, including VEGF 121 and VEGF 165 . However, the clinical potential as blood biomarkers in EGFR-TKI treatment remains unclear.

Methods

We retrospectively analyzed 64 patients with advanced EGFR -mutated NSCLC who received EGFR-TKI monotherapy at Hiroshima University Hospital between November 2009 and August 2023. Pre-treatment serum levels of total VEGF-A (tVEGF-A), VEGF 121 , and VEGF 165 were measured using enzyme-linked immunosorbent assays. The association of these biomarkers with the objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) was analyzed.

Results

The ORR was 78.1%, and the median PFS and OS were 7.5 and 31.8 months, respectively. Serum VEGF 121 levels were significantly higher in non-responders than in responders (median, 446.6 vs. 322.1 pg/mL, p = 0.043), whereas no significant differences were observed for tVEGF-A and VEGF 165 levels. Receiver operating characteristic analysis identified an optimal serum VEGF 121 cut-off level of 339.3 pg/mL (AUC: 0.678, sensitivity: 52.0%, specificity: 92.9%). Patients with higher serum VEGF 121 (> 339.3 pg/mL) had significantly lower ORR (64.9% vs. 96.3%, p = 0.003), shorter PFS (median, 6.2 vs. 14.4 months, p = 0.026), and shorter OS (median, 27.6 months vs. not reached, p = 0.040) than those with lower serum VEGF 121 (≤ 339.3 pg/mL).

Conclusion

Higher levels of serum VEGF 121 were associated with lower EGFR-TKI efficacy and poorer prognosis in patients with EGFR -mutated NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungVascular Endothelial Growth Factor AProtein Kinase InhibitorsLung NeoplasmsHumansFemaleErbB ReceptorsMaleAgedMiddle AgedMutationRetrospective StudiesBiomarkers, TumorAged, 80 and overProtein IsoformsAdultPrognosis

Stichwörter der Autor:innen

BiomarkerEpidermal growth factor receptorNon-small cell lung cancerTyrosine kinase inhibitorVEGF121Vascular endothelial growth factor-A

Substanzen

Vascular Endothelial Growth Factor AErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanVEGFA protein, humanBiomarkers, TumorProtein Isoforms

Autor:innen und Institutionen

  • Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
  • Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan. yamaguchikakuhiro@gmail.com.
  • Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Förderung

  • Hiroshima University

Zitieren

APA

Hirakawa, T., Yamaguchi, K., Shimoji, K., Sakamoto, S., Horimasu, Y., Masuda, T., Nakashima, T., Iwamoto, H., Hamada, H., & Hattori, N. (2026). Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs. International Journal of Clinical Oncology, 31(8), 1696-1705. https://doi.org/10.1007/s10147-026-03083-2

Vancouver

Hirakawa T, Yamaguchi K, Shimoji K, Sakamoto S, Horimasu Y, Masuda T, et al. Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs. International Journal of Clinical Oncology. 2026;31(8):1696-1705. doi:10.1007/s10147-026-03083-2

BibTeX
@article{Hirakawa2026,
  author = {Hirakawa, Tetsu and Yamaguchi, Kakuhiro and Shimoji, Kiyofumi and Sakamoto, Shinjiro and Horimasu, Yasushi and Masuda, Takeshi and Nakashima, Taku and Iwamoto, Hiroshi and Hamada, Hironobu and Hattori, Noboru},
  title = {Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {8},
  pages = {1696--1705},
  doi = {10.1007/s10147-026-03083-2}
}
Kostenlos starten →